Annals of Pathology and Laboratory Medicine https://www.pacificejournals.com/journal/index.php/apalm <p><strong>Annals of Pathology and Laboratory Medicine (APALM)</strong> is an international, Double-blind peer-reviewed, indexed, open access, online and print journal&nbsp;for pathologists, microbiologist, biochemist and clinical laboratory scientists, and is published by <strong><a href="https://www.pacificejournals.com" target="_blank" rel="noopener"><strong>Pacific group of e-Journals</strong>' (<strong>PaGe</strong>)</a>, </strong>an&nbsp;<em>ISO 9001:2008</em> Certified&nbsp;academic publishing house.</p> <p>Set up in 2014, APALM is a specialized journal, which publishes original, peer-reviewed articles&nbsp;in the field of Pathology and Laboratory Medicine which, <em>inter alia</em>, includes Histopathology, Cytopathology, Hematology, Clinical Pathology, Forensic Pathology, Blood Banking, Clinical Bio-Chemistry, Medical Microbiology (Bacteriology, Virology, Mycology, Parasitology), etc.</p> <p><strong>DOI: 10.21276/APALM (<a title="Verify APALM DOI " href="https://dx.doi.org/10.21276/apalm" target="_blank" rel="noopener">https://dx.doi.org/10.21276/apalm</a>)<br></strong></p> <p>&nbsp;</p> Pacific Group of e-Journals (PaGe) en-US Annals of Pathology and Laboratory Medicine 2394-6466 <p>Authors who publish with this journal agree to the following terms:</p> <ol> <li class="show">Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a&nbsp;<a href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</a>&nbsp;that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li> <li class="show">Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li> <li class="show">Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See&nbsp;The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).</li> </ol> <p>&nbsp;</p> Investigation of Transfusion Adverse Events Patterns in Fayoum University Hospitals, Egypt: Hemovigilance Initiative https://www.pacificejournals.com/journal/index.php/apalm/article/view/3226 <p><strong>Background and Objective:</strong> Hemovigilance is an adverse reaction surveillance and monitoring system to improve the safety and quality of blood transfusion in terms of corrective and preventive action.&nbsp; Identification of the adverse reactions and their risk factors will assist in taking appropriate steps to reduce their incidence and make blood transfusion safer. The aim of our study was to analyze the nature and incidence of transfusion related adverse events as a tool for implementation of hemovigilance system in Egypt.</p> <p><strong>Study Design and Methods:</strong> Our study included all transfusion related adverse reactions from Fayoum University Hospital reported to the Blood Bank over a period of one year from August 2021 to July 2022.&nbsp; All patients receiving transfusion and all blood donors according to The National Blood Transfusion Guidelines were included.&nbsp; All reported reactions were analyzed, categorized and evaluated.</p> <p><strong>Results:</strong> 28, 253 blood and blood components units were issued to 13, 544 patients. 273 (0.967%) transfusion related adverse reactions were reported to the blood bank. The most common reaction observed in recipients was allergic reaction 129 (47.25 %) followed by febrile non hemolytic transfusion reaction (FNHTR) 108 (39.56 %).</p> <p><strong>Conclusion:</strong> Data related to transfusion related adverse reactions in developing countries are rare in literature. A strict quality assurance measures are required to build a hemovigilance system including, appropriate use of blood, maintain blood cold chain, monitoring, documenting and reporting transfusion reactions so that, the proper hemovigilance system can be attained.</p> Abeer Mohamed Abdelrazik Rhogenie Baselly Sauza Hossam Mahmoud Abdelaziz ##submission.copyrightStatement## http://creativecommons.org/licenses/by/4.0 2023-02-07 2023-02-07 10 1 A1 7 10.21276/apalm.3226